CPG-oligonucleotide
Showing 1 - 25 of 183
Advanced Malignant Solid Tumor, Extracranial Solid Tumor, Metastatic Malignant Solid Tumor Trial in Palo Alto (Anti-OX40
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Anti-OX40 Antibody BMS 986178
- TLR9 Agonist SD-101
-
Palo Alto, CaliforniaStanford Cancer Institute Palo Alto
Jun 13, 2022
Plague, Pneumonic, Plague, Vaccine-Preventable Diseases Trial in United States (rF1V vaccine and CpG 1018® adjuvant, rF1V
Recruiting
- Plague, Pneumonic
- +2 more
- rF1V vaccine and CpG 1018® adjuvant
- rF1V vaccine
-
Huntsville, Alabama
- +4 more
Aug 16, 2022
Lung Cancer, Hepatocellular Carcinoma, Solid Tumor Trial in Guangzhou (CpG-ODN)
Recruiting
- Lung Cancer
- +2 more
- CpG-ODN
-
Guangzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Jun 27, 2021
Mild Cognitive Impairment, Alzheimer Dementia Trial (CpG1018, Placebo)
Not yet recruiting
- Mild Cognitive Impairment
- Alzheimer Dementia
- CpG1018
- Placebo
- (no location specified)
Jan 3, 2023
Liver Metastasis Colon Cancer Trial (IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN)
Not yet recruiting
- Liver Metastasis Colon Cancer
- IRE plus checkpoint inhibitor
- IRE plus Checkpoint Inhibitor plus CpG-ODN
- (no location specified)
Sep 13, 2023
COVID-19 Trial in Kyiv, Vinnitsa (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix, Placebo; 0.9% saline)
Terminated
- COVID-19
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine
- +2 more
-
Kyiv, Ukraine
- +3 more
May 19, 2022
Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)
Recruiting
- Minimal Residual Disease
- +11 more
- ELI-002 2P
-
Duarte, California
- +10 more
Jan 18, 2023
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, NSCLC Trial (ELI-002 7P)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- +14 more
- ELI-002 7P
- (no location specified)
Feb 3, 2023
COVID-19 Trial in Adelaide (Advax-CpG55.2 adjuvanted recombinant spike protein)
Recruiting
- COVID-19
- Advax-CpG55.2 adjuvanted recombinant spike protein
-
Adelaide, South Australia, AustraliaARASMI
Aug 15, 2022
COVID-19 Trial in Nedlands (SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant)
Completed
- COVID-19
- SCB-2019
- +3 more
-
Nedlands, Western Australia, AustraliaLinear Clinical Research Ltd
Feb 17, 2022
Effectiveness of Standard Therapy of Acne Vulgaris
Completed
- Acne Vulgaris
-
Jakarta Pusat, Jakarta, Indonesiadr.Cipto Mangunkusumo National Central General Hospital
Aug 7, 2023
Pain, Dementia Trial (Pain-CPG-EIT, Pain-CPG-Education Only)
Not yet recruiting
- Pain
- Dementia
- Pain-CPG-EIT
- Pain-CPG-Education Only
- (no location specified)
May 12, 2023
Tuberculosis Trial in Shanghai (Placebo, Low dose adjuvant, High dose adjuvant)
Completed
- Tuberculosis
- Placebo
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Public Health clinical Center
Mar 9, 2022
Healthcare Worker, Hepatitis B Vaccine, Nonresponder Trial in Madison (Recombinant hepatitis B vaccine with CpG adjuvant)
Recruiting
- Healthcare Worker, Hepatitis B Vaccine, Nonresponder
- Recombinant hepatitis B vaccine with CpG adjuvant
-
Madison, WisconsinUniversity of Wisconsin
Jul 5, 2022
Solid Tumor Trial in Seoul (TASO-001((TGF-ß2 targeting anti-sense oligonucleotide), Aldesleukin)
Recruiting
- Solid Tumor
- TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
- Aldesleukin
-
Seoul, Korea, Republic ofSeoul National University Hospital
Jan 31, 2023
COVID-19 Trial in Worldwide (CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Placebo; 0.9% saline, SCB-2019 vaccine)
Recruiting
- COVID-19
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine
- +3 more
-
Alken, Belgium
- +30 more
Feb 7, 2022
Clinical Practice Guidelines, Lower Limb Amputation Above Knee (Injury), Lower Limb Amputation Below Knee (Injury) Trial in
Completed
- Clinical Practice Guidelines
- +7 more
- Telehealth-based strategy
-
Medellín, Antioquia, ColombiaUniversidad de Antioquia
Nov 2, 2022
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston
Recruiting
- Mantle Cell Lymphoma
- +9 more
- L-Bcl-2 antisense oligonucleotide
-
Augusta, Georgia
- +2 more
Nov 18, 2022
Hepatitis B Trial in Baltimore, Falls Church (Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B])
Withdrawn
- Hepatitis B
- Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
-
Baltimore, Maryland
- +1 more
Jul 19, 2022
Bladder Cancer, Urothelial Carcinoma Trial in United States (OGX-427, Docetaxel)
Completed
- Bladder Cancer
- Urothelial Carcinoma
-
Birmingham, Alabama
- +34 more
Jul 7, 2022
Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)
Recruiting
- Myeloid Malignancies
- Lymphoid Malignancies
- NK Cell enriched-DLI only
- NK-DLI + DUK-CPG-001
-
Durham, North CarolinaDuke University Health System
Mar 8, 2022
Covid19 Trial in Canada, United States (Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo)
Active, not recruiting
- Covid19
- Low Dose of KBP-COVID-19
- +2 more
-
West Palm Beach, Florida
- +7 more
Aug 15, 2022
Rheumatoid Arthritis Trial in Canada, United States (ISIS 104838)
Completed
- Rheumatoid Arthritis
- ISIS 104838
-
Birmingham, Alabama
- +30 more
Dec 1, 2022